Literatur
-
01
Ainsworth
S B, Beresford
M W, Milligan
D WA, Shaw
N J, Matthews
J NS, Fenton
A C, Ward Platt
M P.
Pumactant and poractant alfa for treatment of respiratory
distress syndrome in neonates born at 25 - 29 weeks'
gestation: a randomised trial.
Lancet.
2000;
355
1387-1392
-
02
Findlay
R D, Taeusch
H W, Walther
F J.
Surfactant replacement therapy for meconium aspiration
syndrome.
Pediatrics.
1996;
97
48-52
-
03
Gan X, Jarstrand
C, Herting E, Berggren
B, Robertson B.
Effect of surfactant and specific antibody on bacterial
proliferation and lung function in experimental pneumococcal pneumonia.
Int J Infect Dis (in press).
-
04
Halliday H L.
Natural vs synthetic surfactants in neonatal respiratory
distress syndrome.
Drugs.
1996;
51
226-237
-
05
Herting E, Gan
X, Rauprich P, Jarstrand
C, Robertson B.
Combined treatment with surfactant and specific
immunoglobulin reduces bacterial proliferation in experimental neonatal group
B-streptococcal pneumonia.
Am J Respir Crit Care Med.
1999;
159
1862-1867
-
06
Herting E, Gefeller
O, Land M, van Sonderen
L, Harms K, Robertson
B and members of the Collaborative European Multicenter Study
Group.
Surfactant treatment of neonates with respiratory failure and
group B-streptococcal infection.
Pediatrics.
2000;
106
957-964
-
07
Herting E, Jarstrand
C, Rasool O, Curstedt
T, Sun B, Robertson
B.
Experimental neonatal group B streptococcal pneumonia: Effect
of a modified porcine surfactant on bacterial proliferation in ventilated
near-term rabbits.
Pediatr Res.
1994;
36
784-791
-
08
Jobe A H.
Pulmonary surfactant therapy.
N Engl J Med.
1993;
328
861-868
-
09
Kobayashi T, Ohta
K, Tashiro K, Nishizuka
K, Chen W-M, Ohmura
S, Yamamoto K.
Dextran restores albumin-inhibited surface activity of
pulmonary surfactant extract.
J Appl Physiol.
1999;
86
1778-1784
-
10
Lu K W, Taeusch
H W, Robertson
B, Goerke J, Clements
J A.
Polymer-surfactant treatment of meconium-induced acute lung
injury.
Am J Respir Crit Care Med.
2000;
162
623-628
-
11
Rauprich P, Möller
O, Walter G, Herting
E, Robertson B.
Influence of modified natural or synthetic surfactant
preparations on growth of bacteria causing infections in the neonatal
period.
Clin Diagn Lab Immunol.
2000;
7
817-822
-
12
Seeger W, Grube
C, Günther A, Schmidt
R.
Surfactant inhibition by plasma proteins: differential
sensitivity of various surfactant preparations.
Eur Respir J.
1993;
6
971-977
-
13
Stichtenoth G, Herting
E, Rauprich P, Walter
G, Johansson J, Robertson
B.
Inhibition of surfactant preparations used for treatment of
neonatal acute respiratory distress syndrome (ARDS) caused by meconium
aspiration: surface tension vs. area compression.
Biol Neonate.
2000;
77 (Suppl 1)
25-26
-
14
Taeusch H W, Lu
K W, Goerke
J, Clements J A.
Nonionic polymers reverse inactivation of surfactant by
meconium and other substances.
Am J Respir Crit Care Med.
1999;
159
1391-1395
-
15
Tashiro K, Kobayashi
T, Robertson B.
Dextran reduces surfactant inhibition by meconium.
Acta Paediatr.
2000;
89
1439-1445
-
16
Wang Y, Griffiths
W J, Curstedt
T, Johansson J.
Porcine pulmonary surfactant preparations contain the
antibacterial peptide prophenin and a C-terminal 18-residue fragment
thereof.
FEBS Letters.
1999;
460
257-262
Prof. Bengt RobertsonMD
Laboratory for Surfactant Research
Karolinska Hospital
L73
17176 Stockholm
Sweden
Telefon: + 468 517 76 160
Fax: + 468 517 76 165
eMail: Bengt.Robertson@mb.ks.se
